<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009720</url>
  </required_header>
  <id_info>
    <org_study_id>S2361</org_study_id>
    <nct_id>NCT04009720</nct_id>
  </id_info>
  <brief_title>RESPOND EDGE Post Market Study</brief_title>
  <acronym>RESPOND EDGE</acronym>
  <official_title>Repositionable Lotus Edge™ Valve System - Post Market Evaluation of Real World Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the RESPOND EDGE post market study is to collect real world clinical and
      device performance outcomes data with the Lotus Edge™ Valve System used in routine clinical
      practice to demonstrate that the commercially available Lotus Edge Valve System is a safe and
      effective treatment for patients with severe calcific aortic stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RESPOND EDGE study is a prospective, open label, single arm, multi-center, observational
      post market study designed to collect real world clinical and device performance outcomes
      data of the commercially available Lotus Edge Valve used in routine clinical practice for the
      treatment of severe calcific aortic stenosis. Approximately 200 real-world, consecutive
      subjects will be enrolled at up to 20 study centers. The study duration for each subject is
      expected to be approximately 2 years. Implanted subjects will be contacted for follow-up at
      30 days, 1 and 2 years post index procedure. Subjects who are enrolled but not implanted with
      a Lotus Edge valve will be followed for safety through 30 days after the initial attempted
      index procedure.

      Collection of safety events will include any serious adverse event (SAE), serious adverse
      device effect (SADE), adverse device effect (ADE), unanticipated serious adverse device
      effect (USADE), and all Valve Academic Research Consortium (VARC) events regardless of
      seriousness and device relationship through 2 year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>All-cause mortality (Primary Safety Endpoint)</measure>
    <time_frame>30 days</time_frame>
    <description>The primary safety endpoint is all-cause mortality at 30 days after the implant procedure. The primary safety endpoint will be evaluated on an intention to- treat (ITT) basis (all subjects enrolled, whether or not a Lotus Edge Valve is implanted).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean aortic valve pressure gradient (Primary Effectiveness Endpoint)</measure>
    <time_frame>Within 7 days after the index procedure (Pre-discharge)</time_frame>
    <description>The primary effectiveness endpoint is the mean aortic valve pressure gradient (mmHg) at pre-discharge as determined by an independent core laboratory. The primary analysis set for the primary effectiveness endpoint is the implanted analysis set.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotus Edge Device</intervention_name>
    <description>The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] &lt;1.0 cm2 or AVA index &lt;0.6 cm2/m2) who are at high risk for standard surgical valve replacement.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed
        the Informed Consent Form and are selected to receive a LOTUS Edge valve will be evaluated
        for enrollment in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects will be evaluated for eligibility by the clinical center's heart team per the
        local standard of practice in accordance with the Directions for Use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Dumonteil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh K Kharbanda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford Heart Centre, John Radcliffe Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Cornaille, MSc</last_name>
    <phone>+33 608863659</phone>
    <email>Anne.Cornaille@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Soendergaard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lars Soendergaard, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Helsinki</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mika Laine, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mika Laine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Dumonteil, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Dumonteil, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Mylotte, MD</last_name>
    </contact>
    <investigator>
      <last_name>Darren Mylotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az Osp Univ Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Petronio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anna Petronio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas van Mieghem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas M van Mieghem, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Bjursten, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henrik Bjursten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Belfast</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Spence, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Spence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hildick-Smith, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Hildick-Smith, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Blackman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Blackman, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh K Kharbanda, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rajesh K Kharbanda, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cotton, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Cotton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

